ArticleInternational journal of genomics2025
Impact of Genetic Polymorphisms on the Efficacy and Safety of Isoniazid in Saudi Tuberculosis Patients.
Article in International journal of genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Impact of Genetic Polymorphisms on the Efficacy and Safety of Isoniazid in Saudi Tuberculosis Patients.International journal of genomics · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Responses to antitubercular drugs like isoniazid (INH) are influenced by genetic polymorphisms in metabolizing enzymes and transporters. Objectives: This study is aimed at analyzing genetic polymorphisms of NAT2, CYP2E1, and GSTM1 genes in Saudi TB patients, monitoring INH drug levels, and exploring correlations between these genetic variations, drug levels, hepatotoxicity incidence, and clinical outcomes. Method: This prospective cohort design was conducted at King Abdul-Aziz University Hospital in Jeddah, Saudi Arabia. It followed 50 TB patients undergoing first-line anti-TB treatment for 6 months. Genotyping and INH serum concentration measurements were conducted. Results: The mean INH plasma drug levels measured in 30 patients were 2.86 ± 2.80. The presence or absence of the GSTM1 does not statistically affect the plasma INH level between the TB patients with no significant association between GSTM1 and clinical response, while high plasma concentration of INH was significantly associated with improved clinical response. The present study demonstrated no NAT2 and CYP2E1 gene variations in Saudi TB patients but has identified a GSTM1 variant in 68% of patients. The presence or absence of the GSTM1 gene variant appears to not affect INH drug level or clinical outcomes. Conclusion: Clinicians should consider individualized TB treatment based on genetic and demographic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.